Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Medpace stock | $140.12

Own Medpace stock in just a few minutes.

Fact checked

Medpace Holdings, Inc is a diagnostics & research business based in the US. Medpace shares (MEDP) are listed on the NASDAQ and all prices are listed in US Dollars. Medpace employs 3,400 staff and has a trailing 12-month revenue of around USD$896.1 million.

How to buy shares in Medpace

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Medpace. Find the stock by name or ticker symbol: MEDP. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Medpace reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$140.12, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Medpace, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Medpace. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Medpace share price

Use our graph to track the performance of MEDP stocks over time.

Medpace shares at a glance

Information last updated 2020-12-30.
Latest market closeUSD$140.12
52-week rangeUSD$58.72 - USD$150.57
50-day moving average USD$131.7782
200-day moving average USD$117.8123
Wall St. target priceUSD$127.5
PE ratio 42.4476
Dividend yield N/A (0%)
Earnings per share (TTM) USD$3.289

Buy Medpace shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
$0 for US stocks
Stocks, Options, ETFs
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Medpace stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Medpace price performance over time

Historical closes compared with the close of $140.12 from 2020-12-18

1 week (2021-01-08) -1.16%
1 month (2020-12-15) -2.78%
3 months (2020-10-15) 10.89%
6 months (2020-07-15) 33.37%
1 year (2020-01-15) 57.21%
2 years (2019-01-15) 131.72%
3 years (2018-01-12) 277.68%
5 years (2016-01-11) N/A

Is Medpace under- or over-valued?

Valuing Medpace stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Medpace's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Medpace's P/E ratio

Medpace's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 42x. In other words, Medpace shares trade at around 42x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Medpace's PEG ratio

Medpace's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.97. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Medpace's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Medpace's EBITDA

Medpace's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$167.5 million.

The EBITDA is a measure of a Medpace's overall financial performance and is widely used to measure a its profitability.

Medpace financials

Revenue TTM USD$896.1 million
Operating margin TTM 16.54%
Gross profit TTM USD$540 million
Return on assets TTM 7.82%
Return on equity TTM 16.76%
Profit margin 13.87%
Book value $22.263
Market capitalisation USD$5 billion

TTM: trailing 12 months

Shorting Medpace shares

There are currently 996,708 Medpace shares held short by investors – that's known as Medpace's "short interest". This figure is 32.1% up from 754,369 last month.

There are a few different ways that this level of interest in shorting Medpace shares can be evaluated.

Medpace's "short interest ratio" (SIR)

Medpace's "short interest ratio" (SIR) is the quantity of Medpace shares currently shorted divided by the average quantity of Medpace shares traded daily (recently around 220510.61946903). Medpace's SIR currently stands at 4.52. In other words for every 100,000 Medpace shares traded daily on the market, roughly 4520 shares are currently held short.

However Medpace's short interest can also be evaluated against the total number of Medpace shares, or, against the total number of tradable Medpace shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Medpace's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Medpace shares in existence, roughly 30 shares are currently held short) or 0.0528% of the tradable shares (for every 100,000 tradable Medpace shares, roughly 53 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Medpace.

Find out more about how you can short Medpace stock.

Medpace share dividends

We're not expecting Medpace to pay a dividend over the next 12 months.

Medpace share price volatility

Over the last 12 months, Medpace's shares have ranged in value from as little as $58.72 up to $150.57. A popular way to gauge a stock's volatility is its "beta".

MEDP.US volatility(beta: 1.35)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Medpace's is 1.3456. This would suggest that Medpace's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Medpace overview

Medpace Holdings, Inc., a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is headquartered in Cincinnati, Ohio.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site